|Application ||WB, E|
|Calculated MW||67792 Da|
|Antigen Region||7-34 aa|
|Other Names||Coagulation factor XII, Hageman factor, HAF, Coagulation factor XIIa heavy chain, Beta-factor XIIa part 1, Beta-factor XIIa part 2, Coagulation factor XIIa light chain, F12|
|Target/Specificity||This F12 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 7-34 amino acids from the N-terminal region of human F12.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||F12 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI.
Houlihan, L.M., et al. Am. J. Hum. Genet. 86(4):626-631(2010)
Calafell, F., et al. Hum. Mol. Genet. 19(3):517-525(2010)
Katakami, N., et al. Diabetes Care 33(2):390-395(2010)
Back, J., et al. Biochem. Biophys. Res. Commun. 391(1):11-17(2010)
Joseph, K., et al. Ann. Allergy Asthma Immunol. 104(1):50-54(2010)
Bunkenborg, J., et al. Proteomics 4(2):454-465(2004)
Hiller, O., et al. J. Biol. Chem. 275(42):33008-33013(2000)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.